Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.59 |
| ▸ | FAAH | O00519 | 5/20 | 0.56 |
| ▸ | NAAA | Q02083 | 1/20 | 0.55 |
| ▸ | CNR1 | P21554 | 2/20 | 0.54 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5536463 | 0.94 | FAAH (0.59) | CASP2FAAHNAAACNR1DNM1 | |
| SCHEMBL7552938 | 0.92 | FAAH (0.62) | CASP2FAAHNAAACNR1DNM1 | |
| SCHEMBL5544292 | 0.92 | FAAH (0.62) | CASP2FAAHNAAACNR1DNM1 | |
| SCHEMBL5539151 | 0.92 | CASP2 (0.71) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL3033120 | 0.92 | CASP2 (0.59) | CASP2FAAHNAAACNR1DNM1 | |
| SCHEMBL7287736 | 0.90 | CASP2 (0.62) | CASP2FAAHNAAACNR1DNM1 | |
| SCHEMBL9033932 | 0.90 | FAAH (0.65) | CASP2FAAHNAAACNR1DNM1 | |
| SCHEMBL5537118 | 0.89 | CNR1 (0.51) | CASP2FAAHNAAACNR1DNM1 | |
| SCHEMBL295180 | 0.89 | CASP2 (0.61) | CASP2FAAHNAAACNR1DNM1 | |
| SCHEMBL7346940 | 0.88 | CASP2 (0.66) | CASP2FAAHNAAACNR1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| CN-100508975-C | Use of pyrazolopyridine compound | ASTELLAS PHARMA INC (JP) | 2009-07-08 | — | — | CN | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| US-7026297-B2 | Neuroprotective agents | UNIVERSITY OF SOUTHAMPTON (GB) | 2006-04-11 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-20050124554-A1 | Spermidine derivatives for the treatment of chronic neurodegenerative diseases | SOUTHAMPTON, UNIVERSITY OF (GB) | 2005-06-09 | — | — | US | disclosed |
| EP-1471901-A1 | SPERMIDINE DERIVATIVES FOR THE TREATMENT OF CHRONIC NEURODEGENERATIVE DISEASES | UNIVERSITY OF SOUTHAMPTON (GB) | 2004-11-03 | — | — | EP | disclosed |
| US-6797699-B1 | EXEMPLIFIED BY N'-L-ARGINYLSPERMIDINE | UNIVERSITY OF SOUTHAMPTON (GB) | 2004-09-28 | — | — | US | disclosed |
| WO-1991005549-A1 | BENZOHETEROCYCLIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-05-02 | — | — | WO | disclosed |
| EP-0200915-B1 | AMINOPROPANOL DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AND MEDICINES CONTAINING THEM | Roche Diagnostics GmbH (DE) | 1989-09-27 | — | — | EP | disclosed |
| US-4863949-A | CARDIOVASCULAR DISORDER TREATMENT | BOEHRINGER MANNHEIM GMBH (DE) | 1989-09-05 | — | — | US | disclosed |
| EP-0280951-A1 | Amino-propanol derivatives, process for their preparation and medicines containing these compounds, as well as intermediates | Roche Diagnostics GmbH (DE) | 1988-09-07 | — | — | EP | disclosed |
| EP-0200915-A1 | Aminopropanol derivatives, process for their preparation, their use and medicines containing them | Roche Diagnostics GmbH (DE) | 1986-11-12 | — | — | EP | disclosed |
| US-4101464-A | Process for preparing foamed solids using two or more azo compounds | PENNWALT CORPORATION (US) | 1978-07-18 | — | — | US | disclosed |
| US-4069377-A | Polymerization of ethylenically unsaturated monomers employing secondary-aliphatic α-substituted azoalkanes | PENNWALT CORPORATION | 1978-01-17 | — | — | US | disclosed |
| US-4029615-A | AZO COMPOUNDS | PENNWALT CORPORATION (US) | 1977-06-14 | — | — | US | disclosed |
| US-4025502-A | POLYMERIZATION CATALYSTS, CURING AGENTS | PENNWALT CORPORATION (US) | 1977-05-24 | — | — | US | disclosed |
| US-3993609-A | ACID SENSITIVE AZO PROMOTERS | PENNWALT CORPORATION (US) | 1976-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | CASP2 2099/4885FAAH 4363/4885NAAA 2414/4885 |
| US-20050124554-A1 | Spermidine derivatives for the treatment of chronic neurodegenerative diseases | SRM, SMS, PARK7 | CASP2 2102/4885FAAH 3915/4885NAAA 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.